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A new stefin type low-M, cysteine proteinase inhibitor (PLCPI) was isolated from pig polymorphonuclear leukocytes as a contaminant of the 
cathelin sample. The inhibitor consists of 103 amino acids, and its M, was calculated to be 11,768. The inhibitor exhibits considerable sequence 
identity with inhibitors from the stefin family, particularly with human stefin A. The PLCPI is a fast acting inhibitor of papain and cathepsins 
L and S (k,% 2 1 x lo6 M-’ .s-‘) and forms very tight complexes with these enzymes (K, I 190 PM). The affinity for cathepsins B and H (K, 2 125 nM) 
was lower. These results also show that the inhibitory activity previously ascribed to cathelin was due to the presence of PLCPI. 
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1. INTRODUCTION 
Stefins are a group of cysteine proteinase inhibitors 
which may (as well as the members of the other two 
families of the cystatin superfamily, cystatins and kinin- 
ogens) be involved in the control mechanism responsi- 
ble for protein degradation. They act as tight and 
reversibly binding inhibitors of the papain-like intracel- 
lular cysteine proteinases [ 11. Although it was suggested 
that stefins are intracellular proteins, there are some 
indications that they may also function extracellularly 
[2]. So far, mammalian stefins have been isolated and 
characterized from human, rat [l] and bovine tissues 
[3,4]. All stefins are acidic proteins with M, of about 
11,000 and without carbohydrates and disulphide 
bonds [1,5,6]. Three regions of the inhibitors form close 
contacts with papain: two /3 hairpin loops and the 
amino terminal part [7,8]. The central QVVAG region 
(first B hairpin loop) was found to be highly conserved 
within most of the stefins [6]. In addition, the inhibitory 
properties were not significantly changed if slight mod- 
ifications were present in either of the contact regions 
[9-121. 
An inhibitor of cysteine proteinases, named cathelin, 
*Corresponding author. Fax: (386) (61) 273-594. 
2.1. Materials 
Abbreviations: PLCPI, pig leukocyte cysteine proteinase inhibitor; Bz-, Cm-papain Sepharose was prepared as described [22]. Bz-DL-Arg-2 
benzoyl; Cm-, carboxymethyl; EDTA, ethylenediamine tetraacetic naphtylamide, dithiothreitol and papain (2 x crystallized; EC 3.4.22.2) 
acid; Ep-475, L-3-carboxy-truns-2,3-epoxypropyl-leucylamido- were purchased from Sigma (Germany), Z-Phe-Arg AMC from Serva 
(3guanidino)butane; -AMC, 4-methyl-7-coumarylamide; HPLC, (Germany) and Ep-475 from Peptide Research Foundation (Japan). 
high performance liquid chromatography; PAGE, polyacrylamide gel Papain was further purified according to [23]. Sequencing reagents 
electrophoresis; PITC, phenylisothiocyanate; PTH, phenylthiohydan- were obtained from Applied Biosystems (USA), clostripain (EC 
toin; Z-, benzyloxycarbonyl. 3.4.22.8) from Sigma (Germany) and Staphylococcus aureus V-8 pro- 
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has also been isolated and characterized from pig poly- 
morphonuclear leukocytes [13,14]. Its amino acid se- 
quence exhibited remarkable similarity to the pro- 
regions of several antibacterial peptides, such as bovine 
Bac5 [15], rabbit CAP-18 [16], bovine indolicidin [17], 
rabbit 15-kDa protein [18], and to the homolog of por- 
cine proline/arginine-rich antibacterial peptides [ 191. 
These peptides are also present in large quantities in the 
cytoplasmic granules of polymorphonuclear leukocytes 
and are released after the elastase action [20]. Recently, 
it was shown that pro-Bac5 efficiently inhibits cysteine 
proteinase cathepsin L activity [21]. 
In this paper, we report the isolation and determina- 
tion of the amino acid sequence of the cysteine 
proteinase inhibitor (PLCPI) obtained from pig poly- 
morphonuclear leukocytes. Using a modified isolation 
procedure which was previously applied to the isolation 
of cathelin [13], we found that the cathelin sample was 
composed of two proteins, a stefin type cysteine pro- 
teinase inhibitor (PLCPI) and a non-inhibitory protein 
similar to pro-regions of antibacterial peptides [15-191. 
In addition, the kinetics of the interaction of the PLCPI 
with some papain-like cysteine proteinases was studied. 
2. MATERIALS AND METHODS 
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teinase from Miles Scientific (UK). ChromSpher C8 column 
(100 x 3 mm) was from Chrompack (Netherlands). Human cathepsins 
B (EC 3.4.22.1) and L (EC 3.4.22.15) were puritied as described [24,25] 
as were bovine cathepsins H (EC 3.4.22.16) and S (EC 3.4.22.27) 
[26,27]. All other chemicals used were of analytical or sequential grade. 
2.2. PuriJication procedure 
The PLCPI was purified from the cytosol of pig leukocytes using 
a method that was previously described for the isolation of cathelin 
[13].The isolated sample was further applied to Cm-papain Sepharose. 
The non-bound proteins were removed with Tris buffer (0.1 M, 0.5 M 
NaCl) pH 7.8, and the bound proteins were eluted with 0.01 M NaOH, 
pH 11.5. The pH of eluted fractions was immediately adjusted to pH 
7.5 with 3 M HCl. 
All steps, unless otherwise indicated, were performed at 4°C. 
2.3. Analytical isoelectric focusing 
Analytical isoelectric focusing was performed on Desaga apparatus 
(Pharmacia, Sweden) following the instructions of the manufacturer. 
2.4. Inhibition assay and determination of kinetic constants 
For the routine assays, the papain and cathepsin L inhibitory activ- 
ities of the samples were determined using Bz-DL-Arg-2 naphtylamide 
or Z-Phe-Arg-AMC as substrate [28]. 
Enzymes were active-site titrated by cysteine proteinase inhibitor 
Ep-475. Active-site titrated papin was then used to determine the 
molarity of the inhibitor [4]. 
The equilibrium dissociation constants (4) for the interaction be- 
tween the inhibitor and the cathepsins B and H were determined using 
a stopped assay. Cathepsin B (130 nM final concentration) and 
cathepsin H (25 nM final concentration) were incubated for 20 min 
at 25°C with PLCPI at various concentrations (5&750 nM final con- 
centrations) in 0.1 M phosphate buffer, containing 2 mM dithiothre- 
itol and 1.5 mM EDTA, pH 6.0. Residual activities were determined 
under the same conditions as described previously [28] using BZ-DL- 
Arg-2 naphtylamide as substrate. The K, values were then calculated 
using the modified Ackermann-Potter equation [29]. 
Continuous rate assays using Z-Phe-Arg-AMC as a substrate were 
used for kinetic analysis of papain and cathepsins L and S with PLCPI. 
Variable concentrations of PLCPI and substrate (5 pM for papain, 
10 FM for cathepsin L and 20 PM for cathepsin S) were dissolved in 
1.97 ml of the same buffer, as described above. For cathepsin L 0.34 
M acetate buffer, containing 2 mM dithiothreitol and 1.5 mM EDTA, 
pH 5.5, was used. The reaction was started by the addition of 30 ~1 
of activated papain (380 pM final concentration), cathepsin L (60 pM 
final concentration) or cathepsin S (200 pM final concentration), re- 
spectively. All experiments were done under pseudo-first-order condi- 
tions with PLCPI concentrations at least IO-fold higher than the en- 
zyme concentrations. Data were analysed by non-linear-regression 
analysis according to Morrison [30]. 
2.5. Amino acid analysis 
Samples were hydrolysed in 6.0 M HCl at 1 10°C for 24 h. Analysis 
of the hydrolysates was performed on Applied Biosystems amino acid 
analyser (USA) with pre-column PITC derivatization. 
2.6. Amino acid sequence determination 
Amino acid sequence analyses were performed on an Applied Bio- 
systems 475A liquid-pulse sequencer fitted with an on-line model 120A 
phenylthiohydantoin (PTH) analyzer. 
The PLCPI, dissolved in 0.02 M Tris buffer, containing 0.01 M 
CaCl,, 0.05% (w/w) Brij 35 and 2.0 M urea, pH 7.0, was digested by 
clostripain, which was added in an enzyme-to-substrate mass ratio of 
1:50. The total incubation time was 3 h at 4O“C. 
S. aureus V-8 proteinase cleavage was performed in 0.5 M sodium 
lactate buffer, pH 4.0, at 37’C for 10 h with 2% (w/w) of proteinase. 
Peptides were purified by HPLC (Milton Roy) using a reverse-phase 
ChromSpher C8 column, equilibrated with 0.1% trifluoroacetic acid 
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and acetonitrile for gradient elution. Absorbance was monitored at 
215 nm. 
3. RESULTS AND DISCUSSION 
PLCPI was isolated using the purification scheme for 
cathelin [13]. In addition, the affinity chromatography 
on Cm-papain Sepharose was introduced as a last step. 
The majority of the protein sample (-95%) was eluted 
from the column, while the minor part (-5%) was tightly 
bound to the carrier and could be eluted from the col- 
umn only with 0.01 M NaOH. The non-adsorbed pro- 
tein did not inhibit either papain or cathepsin L. Only 
the Cm-papain Sepharose bound protein exhibited in- 
hibitory activity toward papain and cathepsin L. On 
analytical isoelectric focusing, both samples had the 
same acidic pl value of 4.6 (Fig. 1) and SDS-PAGE 
revealed that the two proteins have the same A4, of 
about 12,000 (not shown). These findings may explain 
why the two different proteins could not be separated 
previously [13]. Affinity chromatography proved to be 
an essential step in this purification procedure, as it 
efficiently separated the inhibitor from the non-inhib- 
itory protein. 
The inhibitor (PLCPI) was further subjected to de- 
tailed kinetic analysis for the interaction with papain 
and cathepsins B, H, L and S. The dependence of the 
observed first order rate constant, kobs, over the range 
of inhibitor concentration was linear, suggesting that 
9.30 - 
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8.45 - 
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6.85 - 
6.55 - 
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5.20 - 
4.55 - 
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PI 
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Fig. 1. Isoelectric focusing of the proteins (1) standards, (2) cathelin 
sample, (3) non-inhibitory protein, (4) PLCPI. 
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inhibition of papain and cathepsins L and S by PLCPI 
occurs in a single step. The k,, kdiss and 4 values are 
presented in Table I. The inhibition of papain and 
cathepsins L and S by PLCPI exhibits k, values be- 
tween 1 x lo6 and 1.35 x lo7 M-l. se1 and kdiss values 
between 1.9 x 10m4 and 6.3 x 10e4 s-l, yielding K,s rang- 
ing from 46 to 190 pM. The determined k,, values are 
comparable to those for the binding of cystatins to the 
same enzymes [l]. Also, the Ki values are similar to 
those previously determined for some other cystatin- 
cysteine proteinase interactions [ 1,2,4,11]. The PLCPI 
is shown to be a fast-acting and tight binding inhibitor 
of papain and cathepsins L and S. In contrast, the inhi- 
bition of cathepsins B and H by PLCPI is weak with Ki 
values of 335 nM and 125 nM, respectively. The former 
constant is in good agreement with the K values for the 
inhibition of human cathepsin B by human and bovine 
stefins B and C [1,12,4]. However, the inhibition of 
cathepsin H by PLCPI is significantly weaker than that 
of any of known stefins [l]. 
The amino acid sequence, as well as the strategy of 
the sequence determination of PLCPI, is presented in 
Fig. 2. Native inhibitor gave an unequivocal sequence 
up to the 40th sequencing cycle (uncleaved molecule in 
Fig. 2). The low initial yield of the run (-10%) indicated 
that a part of the applied material might be N-termi- 
nally blocked. The first set of peptides was obtained by 
clostripain hydrolysis. The sequences of the three CL 
peptides covered almost the whole protein chain (CL2- 
CL4 in Fig. 2). Peptide CL1 could not be sequenced, but 
its amino acid composition corresponds to the N-termi- 
nal sequence of the native molecule with a non-blocked 
terminus. Overlaps of these peptides were provided by 
the second set of peptides generated by the action of S. 
clureus V-8 proteinase (El-E6 in Fig. 2). The C-terminal 
part of the inhibitor was established from CL4 and E6 
peptides. Both peptides ended with Phe, which is not a 
cleavage site of highly specific clostripain or S. aureu.s 
V-8 proteinase. 
From the obtained sequence results, it is evident that 
PLCPI consists of 103 amino acid residues with M, of 
11,768 (Fig. 2). In Fig. 3 the amino acid sequence of 
Table I 
Equilibrium constants (K,) and rate constants (k,, and kdlaa) for the 
inhibition of cysteine proteinases by PLCPI 
Enzyme 
Papain 
Cathepsin B 
Cathepsin H 
Cathepsin L 
Cathepsin S 
lo+ x k,, 
(M-’ . s-‘) 
1.0 f 0.31 
ND 
ND 
5.5 f 0.65 
13.5 + 1.06 
l@xkd,s 
(s-9 
1.9 f 0.39 
ND 
ND 
3.7 + 1.64 
6.3 + 1.25 
(n%) 
0.19 f 0.097 
335 r 50 
125 + 7 
0.067 f 0.036 
0.046 f 0.013 
K, for the papain and cathepsins L and S were calculated from k,,, and 
kdlss values (K, = k,,,Jk,,J. K, for the cathepsins B and H were deter- 
mined by equilibrium inhibition experiments. ND = not determined. 
1 10 20 30 40 50 
xMESEEMLAGGLTEPFC'ATPEIQEIANWKPQLEEKlWKTYE KFEAIIYRS 
native molecule 
I . . . . 
CL1 CL2 
I............... 
El E2 E3 E4 
1 I I 
60 70 80 90 100 
PWAC~~I~I~SLP~QEDP~I~~~DELTGF 
CL3 CL4 
I 
E4 E5 E6 
. . , 
AlaA 5 GlnQ 6 LeUL 7 ser s 3 
ArgR 3 Glu E 12 Lys K 9 Thr T 7 
AsnN 5 Gly G 7 u&M 2 TyrY 6 
AspD 4 H1sx-l 3 PheF 3 va1 v 8 
cyst 0 1le I 7 Pro P 6 TrpW 0 
Total: 103 residues; M,: 11 768 
Fig. 2. The amino acid sequence and composition of PLCPI. CL- 
peptides were derived from clostripain fragmentation and E-peptides 
from S. aureus V-S proteinase hydrolysis. 
PLCPI is aligned with other mammalian stefin-type 
amino acid sequences. PLCPI has 70.4% sequence iden- 
tity with human stefin A, 57.1% with human stefin B 
and rat cystatin fi and 53.1% with rat cystatin a and 
bovine stefins B and C. The level of identity with other 
members of the cystatin superfamily is much lower. 
The partial amino acid sequence of the non-inhib- 
itory protein was also determined and identified as 
cathelin (data not shown) [14]. It has been shown that 
cathelin shares significant similarity with the N-termi- 
nal regions of several antibacterial peptides, such as 
pro-Bac5, proindolicidin, CAP-l 8, 15-kDa protein [ 15- 
18] and homolog of proline/arginine-rich antibacterial 
peptides from porcine bone marrow [ 191, indicating that 
this protein is probably the pro-region or the N-termi- 
nal part analog of pig antibacterial peptide. The se- 
quence alignments of these five proteins show high sim- 
ilarity in the N-terminal parts of the proteins, while the 
C-terminal part possesing the antibacterial activity is 
completely different. From the in vitro experiments of 
the processing of precursors, such as pro-Bac5 and pro- 
Bac7, it has become evident that the elastase is respon- 
sible for the release of antibacterial active peptides Bac5 
and Bac7 [20]. 
From these studies, it is evident that previously de- 
scribed cathelin [14], which very likely corresponds to 
the N-terminal region of pig analog of antibacterial 
pro-peptides [191, does not show any inhibitory activity 
against cysteine proteinases. The observed inhibitory 
activity of the pig cathelin sample [13] is proved to be 
due to the presence of PLCPI. Therefore, the name 
cathelin should be excluded from the terminology of the 
cysteine proteinase inhibitors. The function of a puta- 
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Volume 336, number 2 FEBS LETTERS December 1993 
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HSTA 
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BSTC a 
PCPI 
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Fig. 3. Alignment of amino acid sequences of PLCPI with those of human stefin A (HSTA), rat cystatin a (RCA), human stefin B (HSTB), rat 
cystatin B (RCB), bovine stefin B (BSTB) and bovine stefin C (BSTC). Residues identical to those in porcine inhibitor are marked with ‘shading’, 
numbering is according to human stefin A. 
tive pro-region of mammalian leukocyte antibacterial [14] Ritonja, A., Kopitar, M., Jerala, R. and Turk, V. (1989) FEBS 
peptides therefore has yet to be elucidated. Lett. 225, 211-214. 
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